Our core strength and competitive advantage lie in our established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 biosimilars in the Domestic Market & RoW markets & they are the domestic leader in three biologics. Emcure’s subsidiary - Gennova is leading the creation of India’s first indigenous mRNA vaccine to combat COVID- 19 which is currently under trials.
With 350+ brands, five R&D centers and 14 manufacturing facilities established across the country, we have ensured a strong foothold not just in India but also globally with a wide network across 70+ countries. Our state-of-the-art API facilities ensures that our supply chain is vertically integrated providing flexibility over control of manufacturing. We have cemented strategic global partnerships that are a result of alliances with local and multi-national companies which are at the helm of leadership in key therapeutic areas. The key objective of our widespread presence across markets is to constantly innovate and deliver affordable & high-quality healthcare solutions to people.
Founder CEO and MD
The core values that drive success at Emcure are: